Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
44.71
+0.35 (0.79%)
Sep 16, 2026, 3:30 PM EDT - Market open
Rigel Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 835 | 777 | 296 | 253 | 259 | 453 | |
Market Cap Growth | 22.66% | 162.39% | 17.18% | -2.48% | -42.79% | -23.38% |
Enterprise Value | 780 | 701 | 335 | 295 | 269 | 403 |
Last Close Price | 44.36 | 42.83 | 16.82 | 14.50 | 15.00 | 26.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 2.70 | 2.12 | 16.95 | - | - | - |
Forward PE | 13.83 | 10.49 | 17.39 | - | - | - |
PS Ratio | 3.05 | 2.64 | 1.65 | 2.16 | 2.24 | 3.27 |
PB Ratio | 1.95 | 1.99 | 90.11 | -8.83 | -19.04 | 14.92 |
P/TBV Ratio | 2.55 | 2.12 | - | - | - | 14.92 |
P/FCF Ratio | 10.63 | 10.28 | 9.43 | - | - | 86.30 |
P/OCF Ratio | 10.63 | 10.28 | 9.41 | - | - | 77.10 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.85 | 2.38 | 1.87 | 2.52 | 2.33 | 2.90 |
EV/EBITDA Ratio | 8.79 | 5.48 | 12.69 | - | - | - |
EV/EBIT Ratio | 9.06 | 5.59 | 13.86 | - | - | - |
EV/FCF Ratio | 9.94 | 9.27 | 10.67 | - | - | 76.67 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.14 | 30.40 | -3.64 | -6.44 | 3.01 |
Debt / EBITDA Ratio | 0.44 | 0.41 | 3.68 | - | - | - |
Debt / FCF Ratio | 0.50 | 0.71 | 3.18 | - | - | 17.38 |
Net Debt / Equity Ratio | -0.13 | -0.26 | 6.88 | -1.65 | -2.17 | -1.11 |
Net Debt / EBITDA Ratio | -0.62 | -0.79 | 0.86 | -2.45 | -0.51 | 1.84 |
Net Debt / FCF Ratio | -0.70 | -1.34 | 0.72 | -8.22 | -0.40 | -6.42 |
Asset Turnover | 0.76 | 0.87 | 1.27 | 0.93 | 0.77 | 1.00 |
Inventory Turnover | 3.38 | 3.20 | 5.50 | 2.76 | 5.17 | 10.82 |
Quick Ratio | 1.58 | 2.08 | 1.88 | 1.64 | 1.51 | 2.21 |
Current Ratio | 1.94 | 2.42 | 2.13 | 1.86 | 1.78 | 2.43 |
Return on Equity (ROE) | 126.90% | 185.94% | - | - | -699.04% | -55.63% |
Return on Assets (ROA) | 14.95% | 23.15% | 10.75% | -10.18% | -24.34% | -8.77% |
Return on Invested Capital (ROIC) | 26.02% | 79.47% | 51.25% | -30.81% | -178.67% | -312.65% |
Return on Capital Employed (ROCE) | 20.50% | 30.30% | 24.00% | -32.00% | -85.00% | -18.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 38.13% | 47.21% | 5.90% | -9.92% | -22.59% | -3.95% |
FCF Yield | 9.40% | 9.73% | 10.61% | -2.27% | -28.62% | 1.16% |
Buyback Yield / Dilution | -8.67% | -6.52% | -1.64% | -2.07% | 0.00% | -1.03% |